Pharmakokinetik von Linezolid bei Dialyse (pharmacokinetics of linezolid under dialysis) - LINUS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-002338-39-DE

Enrollment

Registered

2006-08-17

Start date

2006-12-22

Completion date

Unknown

Last updated

2020-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute renal failure and infection or sepsis without acute renal failure

Interventions

Trade Name: Zyvoxid (R) 2mg/ml Infusionslösung Product Name: Zyvoxid (R)2 mg/ml Infusionslösung Pharmaceutical Form: Solution for infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - The receipt of linezolid in the normal treatment of care - acute renale failure with a dialysis-therapy or sepsis without acute renale failure Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - hypersensivity against linezolid - newborn, children, adolescent, pregnant women, nursing women, pre-menopausal women

Design outcomes

Primary

Measure	Time frame
Main Objective: pharmacokinetic of Linezolid under dialysis;Secondary Objective: influence of sepsis alone without dialysis;Primary end point(s): no end points because it is only an accompanying pharmocokinetic-study	—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026